Forchronic is a biotechnolgy company promoted by Canaan Research & Investment, S.L., the Universidad Autónoma de Madrid (UAM) and by researchers from Instituto IMDEA Alimentación and the Hospital Universitario Infanta Sofía, whose objective is to develop and market a new generation of precision nutritional supplements for the prevention and treatment of chronic diseases.
The market targeted by Forchronic is the one commonly known as “Nutraceuticals” which is in strong expansion thanks to the scientific advances that are taking place in the field of food and health.
The new era of nutritional supplements opens up a huge potential in the development of products for specific use for health that establish synergy with current pharmacological treatments.
Forchronic offers an innovative solution based on the development of a new generation of precision and high bioavailability nutraceuticals, with therapeutic activity in chronic diseases such as cancer and several autoimmune pathologies, whose main characteristics are:
- Precision Nutrition: personalization from the genetic and physiological point of view to achieve maximum efficiency.
- High Bioavailability:effective release of compounds in the body with absorption.
- Therapeutic activity: validated capacity in clinical trials in humans.